Research Article | Open Access
DETERMINE THE PHARMACOKINETIC PARAMETERS IN WISTAR ALBINO RATS
NIDHI DOBHAL
Pages: 767-774
Abstract
The medication gliclazide is often used for patients with type 2 diabetes. Studies looking back in time have shown that diabetics are more likely to have serious consequences after an amoebic infection. One of the most used antiamoebic drugs is ornidazole. The purpose of this research was to assess the efficacy and safety of a combination of gliclazide and ornidazole in the treatment of type 2 diabetes in normal rats by monitoring changes in blood sugar levels and observing the drug's activity and pharmacokinetics. Two milligrams of gliclazide per kilogram of body weight and twenty-five milligrams of ornidazole per kilogram of body weight were given orally to normal rats in studies. At predetermined intervals, blood was drawn from the orbital sinuses of the rats. Based on the findings of the current investigation, it seems that ornidazole lacks glucose-lowering efficacy and that any drug-drug interactions between ornidazole and gliclazide are likely of the pharmacokinetic type, with the putative interaction being related to CYP2C9 suppression. It follows that caution is warranted when prescribing ornidazole and gliclazide together for their therapeutic benefit in diabetic patients, and that the dosages may need to be slightly adjusted. But there should be more research done.
Keywords
Albino wistar rats, Cytochrome P 2C9, Gliclazide, HPLC Ornidazole, Pharmacokinetic interactions.